Indaptus Therapeutics, Inc. (INDP)
$1.14-$0.02 (-1.72%) Today
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
No Form 4 activity for INDP in the last 90 days.
16 Form 4 filings on record, the earliest from Oct 10, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| David E. Lazar - Director | Open-market sale | Series AAA Convertible Non-Redeemable Preferred Stock | 700,000 | - | - | |
| David E. Lazar - Director | Open-market sale | Series AA Convertible Non-Redeemable Preferred Stock | 196,800 | - | - | |
| Jerome D. Jabbour - Director | Grant or award | Option to Buy Common Stock | 25,000 | $0.00 | - | |
| Jeffrey A. Meckler - Officer | Derivative | Warrants (right to buy) | 3,033 | - | - | |
| Jeffrey A. Meckler - Officer | Grant or award | Warrants (right to buy) | 3,033 | - | - | |
| Jeffrey A. Meckler - Officer | Derivative | Warrants (right to buy) | 1,519 | - | - | |
| Jeffrey A. Meckler - Officer | Grant or award | Warrants (right to buy) | 1,519 | - | - | |
| Jeffrey A. Meckler - Officer | Derivative | Warrants (right to buy) | 12,136 | - | - | |
| Jeffrey A. Meckler - Officer | Grant or award | Warrants (right to buy) | 12,136 | - | - | |
| Avraham Ben-Tzvi - Director | Grant or award | Common Stock | 25,000 | $0.00 | - | |
| Avraham Ben-Tzvi - Director | Grant or award | Option to Buy Common Stock | 25,000 | $0.00 | - | |
| David Natan - Director | Grant or award | Option to Buy Common Stock | 25,000 | $0.00 | - | |
| Nir Sassi - Officer | Grant or award | Common Stock | 26,758 | $2.03 | $54K | |
| Jeffrey A. Meckler - Officer | Grant or award | Common Stock | 216,617 | $2.03 | $440K | |
| Michael James Newman - Officer | Grant or award | Common Stock | 52,204 | $2.03 | $106K | |
| Walt Addison Linscott - Officer | Grant or award | Common Stock | 54,421 | $2.03 | $110K | |
| Jeffrey A. Meckler - Officer | Grant or award | Common Stock | 6,068 | $8.30 | $50K | |
| Jeffrey A. Meckler - Officer | Grant or award | Common Stock Warrants | 12,136 | $8.30 | $101K | |
| Jeffrey A. Meckler - Officer | Grant or award | Common stock | 42,553 | $32.90 | $50K | |
| Jeffrey A. Meckler - Officer | Grant or award | Common Stock Warrants | 42,553 | $32.90 | $50K | |
| Nir Sassi - Officer | Grant or award | Stock Option (Right to Buy) | 75,000 | $0.00 | - | |
| Roger J. Waltzman - Officer | Grant or award | Stock Option (Right to Buy) | 75,000 | $0.00 | - | |
| Walt Addison Linscott - Officer | Grant or award | Stock Option (Right to Buy) | 75,000 | $0.00 | - | |
| Jeffrey A. Meckler - Officer | Grant or award | Stock Option (Right to Buy) | 75,000 | $0.00 | - | |
| Michael James Newman - Officer | Grant or award | Stock Option (Right to Buy) | 75,000 | $0.00 | - |
Indaptus Therapeutics, Inc. (INDP) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-03-24. The full record for INDP runs to 16 Form 4 filings, the earliest from 2024-10-10. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of INDP were filed in the last 90 days.
No insider sales of INDP were filed in the last 90 days. 2 sales are on record for this company.
This page tracks INDP Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add INDP to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
